This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
LOGC 株式概要
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms.
LogicBio Therapeutics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.07 |
| 52週高値 | US$3.63 |
| 52週安値 | US$0.26 |
| ベータ | 4.62 |
| 11ヶ月の変化 | 0.98% |
| 3ヶ月変化 | 417.63% |
| 1年変化 | -40.35% |
| 33年間の変化 | -76.79% |
| 5年間の変化 | n/a |
| IPOからの変化 | -82.00% |
最新ニュース
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09株主還元
| LOGC | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.5% | -4.0% | 0.6% |
| 1Y | -40.3% | 18.1% | 32.1% |
業界別リターン: LOGC underperformed the US Biotechs industry which returned -15.1% over the past year.
リターン対市場: LOGC underperformed the US Market which returned -21.9% over the past year.
価格変動
| LOGC volatility | |
|---|---|
| LOGC Average Weekly Movement | 179.9% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: LOGC's share price has been volatile over the past 3 months.
時間の経過による変動: LOGC's weekly volatility has increased from 92% to 180% over the past year.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2014 | 62 | Fred Chereau | www.logicbio.com |
LogicBio Therapeutics, Inc. 基礎のまとめ
| LOGC 基礎統計学 | |
|---|---|
| 時価総額 | US$68.23m |
| 収益（TTM） | -US$26.54m |
| 売上高(TTM) | US$10.76m |
6.3x
P/Sレシオ-2.6x
PER（株価収益率LOGC は割高か？
公正価値と評価分析を参照収益と収入
| LOGC 損益計算書（TTM） | |
|---|---|
| 収益 | US$10.76m |
| 売上原価 | US$30.68m |
| 売上総利益 | -US$19.92m |
| その他の費用 | US$6.62m |
| 収益 | -US$26.54m |
直近の収益報告
Sep 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.81 |
| グロス・マージン | -185.15% |
| 純利益率 | -246.71% |
| 有利子負債／自己資本比率 | 37.7% |
LOGC の長期的なパフォーマンスは？
過去の実績と比較を見る